Related Experiment Video

Updated: Jan 7, 2026

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

681

Intertwined roles of microRNA-155 and metformin in osteoarthritis: Novel potential diagnostic, prognostic, and

Mantana Paisan1, Konstantinos I Papadopoulos2, Alexandra Papadopoulou3

  • 1Department of Research and Development, THAI StemLife, Bangkok 10330, Thailand.

World Journal of Orthopedics
|January 2, 2026
PubMed

Insights

MicroRNA-155 (miR-155) plays a key role in osteoarthritis (OA) development. Targeting miR-155 with metformin offers a promising therapeutic strategy for this chronic joint disease.

Area of Science:

  • Biomedical Science
  • Molecular Biology
  • Pharmacology

Background:

  • Osteoarthritis (OA) is a degenerative joint disease with limited treatment options.
  • MicroRNA-155 (miR-155) is implicated in OA pathogenesis and inflammation.
  • Metformin, an antidiabetic drug, shows chondroprotective effects in OA.

Purpose of the Study:

  • To review the role of miR-155 in OA pathophysiology.
  • To explore metformin's potential to modulate miR-155 in OA.
  • To highlight novel therapeutic strategies targeting miR-155 and metformin for OA.

Main Methods:

  • Literature review of studies on miR-155, metformin, and OA.
  • Analysis of molecular pathways involving miR-155 and metformin.
  • Evaluation of therapeutic potential and biomarker applications.

Main Results:

  • miR-155 promotes OA by driving inflammation, cartilage degradation, and chondrocyte apoptosis.
  • Metformin exerts anti-inflammatory and chondroprotective effects in OA via AMPK activation and NF-κB inhibition.
  • Metformin may modulate miR-155 expression, suggesting synergistic therapeutic potential.

Conclusions:

  • miR-155 is a critical factor in OA and a potential diagnostic biomarker.
  • Targeting miR-155, potentially with metformin, presents a novel therapeutic avenue for OA.
  • Innovative treatments involving miR-155 modulation and metformin could modify OA progression.
Keywords:
Adenosine monophosphate-activated protein kinaseCyclooxygenase 2Glucagon-like peptide 1MetforminMicroRNA-155OsteoarthritisRenin-angiotensin aldosterone system

More Related Videos

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as A Novel Detection and Quantification Method09:06

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as A Novel Detection and Quantification Method

Published on: October 7, 2025

306
Tear-Derived Exosomal miR-15a as New Diagnostic Tool for Diabetic Retinopathy07:45

Tear-Derived Exosomal miR-15a as New Diagnostic Tool for Diabetic Retinopathy

Published on: December 30, 2025

88

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.7K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.8K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
559
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K